Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associated with knee osteoarthritis. The regimen is intended to relieve pain for up to 6 months.
Bioventus acquired exclusive U.S. distribution rights for GELSYN from Institut Biochimique in 1Q16. The product had received FDA premarket approval in 2014.
Source: Bioventus LLC
Review Exhibit 115, the Viscosupplement Product Landscape, in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® for a matrix of products cleared and number of injections for various applications around the world.